Science news

<<  return


The US FDA (Food and Drug Administration) approved the use of dabigatran (Pradaxa) for the treatment of deep vein thrombosis and pulmonary embolism in patients who have previously received direct parenteral anticoagulants for 5-10 days or was on the long-term anticoagulant therapy. The basis for this decision was the outcome of  4 studies (RE-COVER, RE-COVER-2, RE MEDY, RE-SONATA).